Danish Danish
en Englishaf Afrikaanssq Albanianar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbg Bulgarianca Catalanzh-CN Chinese (Simplified)zh-TW Chinese (Traditional)hr Croatiancs Czechda Danishnl Dutchet Estoniantl Filipinofi Finnishfr Frenchgl Galicianka Georgiande Germanel Greekht Haitian Creoleiw Hebrewhi Hindihu Hungarianis Icelandicid Indonesianga Irishit Italianja Japaneseko Koreanlv Latvianlt Lithuanianmk Macedonianms Malaymt Malteseno Norwegianfa Persianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsw Swahilisv Swedishth Thaitr Turkishuk Ukrainianur Urduvi Vietnamesecy Welshyi Yiddish

Seneste Nyheder

BioMarin indsender igen Roctavian genterapi til EU-godkendelse

 

Undersøgende genterapi øget FIX-produktion

 

FDA-arkivering for UniQure, CSLs hæmofili B-genterapi planlagt til begyndelsen af ​​2022

 

Genterapi Roctavian forhindrer blødning over 5 år, viser data

 

Tilbage til toppen
Billede

Please enable the javascript to submit this form

Om os

Understøttet af uddannelsesbevillinger fra Bayer, BioMarin, Freeline Therapeutics Limited, Pfizer Inc., Shire, Spark Therapeutics og uniQure, Inc.

Væsentlig SSL